Results 81 to 90 of about 12,875 (250)

Generation and validation of small ADAMTS13 fragments for epitope mapping of anti‐ADAMTS13 autoantibodies in immune‐mediated thrombotic thrombocytopenic purpura

open access: yesResearch and Practice in Thrombosis and Haemostasis, 2020
Background In immune‐mediated thrombotic thrombocytopenic purpura (iTTP), patients develop an immune response against the multidomain enzyme ADAMTS13.
Kadri Kangro   +8 more
doaj   +1 more source

Efficacy of High‐Dose Intravenous Anakinra in Pediatric TAFRO Syndrome: Report of Two Cases and Literature Review

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT TAFRO (thrombocytopenia, anasarca, fever, reticulin fibrosis, renal insufficiency, and organomegaly) syndrome is a rare, life‐threatening inflammatory condition linked to infections, neoplasms, and idiopathic multicentric Castleman disease. Interleukin (IL)‐6 inhibitors are the primary treatment, but refractory cases require alternatives. This
Serena Palmeri   +10 more
wiley   +1 more source

Von Willebrand Factor and ADAMTS13 in COVID-19 and Beyond: A Question of Balance

open access: yesEuropean Medical Journal Nephrology, 2021
von Willebrand factor (VWF) is a large, adhesive, multimeric protein involved in haemostasis. The larger the size (or number of VWF multimers), the greater the functionality of the protein. A deficiency or defect in VWF can lead to von Willebrand disease
Emmanuel J Favaloro   +2 more
doaj  

Anti-ADAMTS13 autoantibody profiling in patients with immune-mediated thrombotic thrombocytopenic purpura.

open access: yesBlood Advances, 2021
Anti-A Disintegrin and Metalloproteinase with a ThromboSpondin type 1 motif, member 13 (ADAMTS13) autoantibodies cause a severe ADAMTS13 deficiency in immune-mediated thrombotic thrombocytopenic purpura (iTTP). ADAMTS13 consists of a metalloprotease (M),
K. Kangro   +15 more
semanticscholar   +1 more source

Healthy Aging Metabolomic and Proteomic Signatures Across Multiple Physiological Compartments

open access: yesAging Cell, EarlyView.
The association of the aging scores with the clinical covariates suggests increased inflammation, strong predisposition to iron deficiency anemia, decline in muscle mass, and renal and hepatic functions with accelerated aging. ABSTRACT The study of biomarkers in biofluids and tissues expanded our understanding of the biological processes that drive ...
R. Moaddel   +17 more
wiley   +1 more source

Shedding Light on the Possible Link between ADAMTS13 and Vaccine—Induced Thrombotic Thrombocytopenia

open access: yesCells, 2021
Several recent reports have highlighted the onset of vaccine-induced thrombotic thrombocytopaenia (VITT) in some recipients (approximately 1 case out of 100k exposures) of the ChAdOx1 nCoV-19 vaccine (AstraZeneca).
A. Szóstek-Mioduchowska, P. Kordowitzki
semanticscholar   +1 more source

Biomarkers of Cellular Senescence in Type 2 Diabetes Mellitus

open access: yesAging Cell, EarlyView.
In cohorts of lean controls, obese participants without Type 2 Diabetes Mellitus (T2DM) and obese T2DM participants, we find that T‐cell expression of senescence biomarkers is altered only in the T2DM participants and not with obesity alone. Moreover, high T‐cell p16 expression in the T2DM participants is associated with impaired bone cortical indices.
Caroline Hoong   +9 more
wiley   +1 more source

Reduced cleavage of von willebrand factor by ADAMTS13 is associated with microangiopathic acute kidney injury following trauma

open access: yesBlood Coagulation and Fibrinolysis, 2021
Supplemental Digital Content is available in the text Acute kidney injury (AKI) is common after trauma, but contributory factors are incompletely understood.
William E Plautz   +14 more
semanticscholar   +1 more source

How we manage immune‐mediated thrombotic thrombocytopenic purpura after rituximab failure or intolerance

open access: yesBritish Journal of Haematology, EarlyView.
The use of rituximab as a pre‐emptive treatment in immune‐mediated thrombotic thrombocytopenic purpura (iTTP) is the current standard of care. However, for patients refractory to rituximab or for those with contraindication, further treatment guidelines are scarce.
Julia Weisinger   +4 more
wiley   +1 more source

Pathogenic variants prevalence patients with diabetic kidney disease in Japan: A descriptive study

open access: yesJournal of Diabetes Investigation, EarlyView.
Previous studies have identified pathogenic variants in 22% of Caucasian patients with diabetic kidney disease (DKD); however, this proportion may vary depending on ethnicity and updates to the database. Whole‐genome sequencing of 79 patients with DKD in Japan revealed that 34.1% had kidney‐related heterozygous pathogenic variants, and 12.7% had ...
Toyohiro Hashiba   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy